newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

  • Ascentage Pharma Group International will release its six months 2026 unaudited interim results & provide business updates on August 19, 2026.
  • The English language investor webcast & Q&A will be held at 8:00 am EDT / 8:00 pm HKT on August 20, 2026.
  • A Chinese (Mandarin) language investor webcast is scheduled for 9:00 pm EDT / 9:00 am HKT on August 20, 2026.
  • Registration is required in advance to access the English & Chinese language investor events.
  • A replay of the English language conference call & presentation will be available on the company website.
  • The company is conducting POLARIS-2, POLARIS-1, & POLARIS-3 Phase III trials for Olverembatinib in CML, Ph+ ALL, & SDH-deficient GIST.
  • Four global registrational Phase III trials for Lisaftoclax are ongoing: GLORA, GLORA-2, GLORA-3, & GLORA-4 for various hematologic malignancies.
  • Ascentage Pharma holds global partnerships with Takeda, AstraZeneca, Merck, Pfizer, & Innovent.
  • The press release includes forward-looking statements subject to risks detailed in the company's SEC filings.
  • Contact information for investor relations is provided as Stella Yang at IR@ascentage.com or +1 (301) 792-6286.